Risk factors for breakthrough PCP in HIV-infected patients receiving aerosol pentamidine

Objective: To identify the risk factors for breakthrough PCP (BPCP) in HIV-infected adult patients receiving aerosol pentamidine (AP) for PCP prophylaxis. Introduction: A large scale community based AP program has been available in Ontario, Canada since May, 1989. Patients receive either 60 mg AP via Fisoneb q 2 weeks or 300 mg via Respirgard. Physicians complete a baseline enrollment forms and provide clinical follow-up at 3 month intervals. …